What is the role of Roxadustat?

At present, the prevalence of renal anemia in China is high, but the awareness rate, treatment rate and standard rate are low. Anemia in patients with chronic kidney disease has not been adequately treated. Renal anemia is an important risk factor leading to the increase of hospitalization rate, cardiovascular disease and death risk. It not only affects the physical and mental health and social functions of patients, but also brings heavy disease burden to their families and society.

Roxadustat benefits significantly from anemia treatment in patients with non-dialysis chronic kidney disease

The new indications for rosalista were approved on the basis of a randomized, double-blind, placebo-controlled phase III clinical study (808 study) in Chinese patients with non-dialysis chronic kidney disease. Professor Chen Nan, chief researcher of phase III clinical trial in China and chief physician of Nephrology of Ruijin Hospital Affiliated to Medical College of Shanghai Jiaotong University, said: "808 results show that rosalis can induce erythropoiesis and can effectively enhance and maintain kidney in patients with anemia who have not received dialysis treatment. Hemoglobin levels in patients with sexual anemia are safe and well tolerated. At the same time, Roxalis is not affected by inflammation when it is used in the treatment of renal anemia. During the clinical trial, it is suggested that there is no need for routine intravenous iron supplementation. In addition, the use of oral dosage forms of rosastatin can help improve patient compliance.